► 1:19 Chronic Phase CML Treatment: A New Drug Option and Discontinuation of TKI Therapy CML Content Hub @GabyHobbs, of @MGHCancerCenter, discusses #asciminib for #CML.
► 24:57 Balancing Toxicity and Response in Ph+ CML Treatment CML Content Hub B Douglas Smith, MD, of @JohnsHopkins, discusses #balance between #toxicity and #response in #CML.
► 4:35 Safety and Efficacy of Asciminib in Third-Line Treatment for CML CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #third-line treatment for #CML.
► 2:12 Well Tolerated in Preliminary Study: Pembrolizumab + TKIs in CML Patients With Persistent Detectible MRD CML Content Hub @Dr_AmerZeidan, of @Yale, discusses #safety of #pembrolizumab plus #TKIs in #CML.
► 2:39 Restoring Sensitivity to TKIs in CML With BCR-ABL1 Mutation CML Content Hub Michael Deininger, MD, PhD, of @MedicalCollege, discusses restoring #sensitivity in #TKI-resistant #CML.
► 1:31 CML Recurrence Mechanism Poorly Understood CML Content Hub Francois-Xavier Mahon, MD, PhD, of @univbordeaux_EN, discusses #recurrence in #CML.
